Share-based Payment Arrangement, Expense of Barinthus Biotherapeutics plc. from 31 Mar 2020 to 30 Sep 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
Barinthus Biotherapeutics plc. quarterly and annual Share-based Payment Arrangement, Expense in USD history and change rate from 31 Mar 2020 to 30 Sep 2025.
  • Barinthus Biotherapeutics plc. Share-based Payment Arrangement, Expense for the quarter ending 30 Sep 2025 was $415,000, a 136% decline year-over-year.
  • Barinthus Biotherapeutics plc. Share-based Payment Arrangement, Expense for the twelve months ending 30 Sep 2025 was $527,000, a 89% decline year-over-year.
  • Barinthus Biotherapeutics plc. annual Share-based Payment Arrangement, Expense for 2024 was $4,709,000, a 6.8% decline from 2023.
  • Barinthus Biotherapeutics plc. annual Share-based Payment Arrangement, Expense for 2023 was $5,055,000, a 49% decline from 2022.
  • Barinthus Biotherapeutics plc. annual Share-based Payment Arrangement, Expense for 2022 was $9,877,000, a 40% decline from 2021.
Source SEC data
View on sec.gov
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Change (%)
Share-based Payment Arrangement, Expense, Annual (USD)
Share-based Payment Arrangement, Expense, YoY Annual Change (%)

Barinthus Biotherapeutics plc. Quarterly Share-based Payment Arrangement, Expense (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q3 2025 $527,000 $415,000 -$1,559,000 -136% 01 Jul 2025 30 Sep 2025 10-Q 07 Nov 2025 2025 Q3
Q2 2025 $2,086,000 $281,000 -$1,476,000 -124% 01 Apr 2025 30 Jun 2025 10-Q 07 Aug 2025 2025 Q2
Q1 2025 $3,562,000 $468,000 -$1,147,000 -71% 01 Jan 2025 31 Mar 2025 10-Q 07 May 2025 2025 Q1
Q4 2024 $4,709,000 $755,000 -$31,000 -3.9% 01 Oct 2024 31 Dec 2024 10-K 20 Mar 2025 2024 FY
Q3 2024 $4,740,000 $1,144,000 +$1,087,000 +1907% 01 Jul 2024 30 Sep 2024 10-Q 07 Nov 2025 2025 Q3
Q2 2024 $3,653,000 $1,195,000 -$795,000 -40% 01 Apr 2024 30 Jun 2024 10-Q 07 Aug 2025 2025 Q2
Q1 2024 $4,448,000 $1,615,000 -$607,000 -27% 01 Jan 2024 31 Mar 2024 10-Q 07 May 2025 2025 Q1
Q4 2023 $5,055,000 $786,000 -$1,255,000 -61% 01 Oct 2023 31 Dec 2023 10-K 20 Mar 2025 2024 FY
Q3 2023 $6,310,000 $57,000 -$1,047,000 -95% 01 Jul 2023 30 Sep 2023 10-Q 06 Nov 2024 2024 Q3
Q2 2023 $7,357,000 $1,990,000 -$758,000 -28% 01 Apr 2023 30 Jun 2023 10-Q 08 Aug 2024 2024 Q2
Q1 2023 $8,115,000 $2,222,000 -$1,762,000 -44% 01 Jan 2023 31 Mar 2023 10-Q 13 May 2024 2024 Q1
Q4 2022 $9,877,000 $2,041,000 -$1,539,000 -43% 01 Oct 2022 31 Dec 2022 10-K 20 Mar 2024 2023 FY
Q3 2022 $11,416,000 $1,104,000 -$2,270,000 -67% 01 Jul 2022 30 Sep 2022 10-Q 09 Nov 2023 2023 Q3
Q2 2022 $13,686,000 $2,748,000 -$5,988,000 -69% 01 Apr 2022 30 Jun 2022 10-Q 10 Aug 2023 2023 Q2
Q1 2022 $19,674,000 $3,984,000 +$3,187,000 +400% 01 Jan 2022 31 Mar 2022 10-Q 12 May 2023 2023 Q1
Q4 2021 $16,487,000 $3,580,000 +$1,380,000 +63% 01 Oct 2021 31 Dec 2021 10-K 24 Mar 2023 2022 FY
Q3 2021 $15,107,000 $3,374,000 +$3,220,000 +2091% 01 Jul 2021 30 Sep 2021 10-Q 10 Nov 2022 2022 Q3
Q2 2021 $11,887,000 $8,736,000 +$8,321,000 +2005% 01 Apr 2021 30 Jun 2021 10-Q 09 Aug 2022 2022 Q2
Q1 2021 $3,566,000 $797,000 -$59,000 -6.9% 01 Jan 2021 31 Mar 2021 10-Q 11 May 2022 2022 Q1
Q4 2020 $3,625,000 $2,200,000 01 Oct 2020 31 Dec 2020 10-K 25 Mar 2022 2021 FY
Q3 2020 $154,000 01 Jul 2020 30 Sep 2020 10-Q 12 Nov 2021 2021 Q3
Q2 2020 $415,000 01 Apr 2020 30 Jun 2020 10-Q 12 Aug 2021 2021 Q2
Q1 2020 $856,000 01 Jan 2020 31 Mar 2020 10-Q 14 Jun 2021 2021 Q1

Barinthus Biotherapeutics plc. Annual Share-based Payment Arrangement, Expense (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2024 $4,709,000 -$346,000 -6.8% 01 Jan 2024 31 Dec 2024 10-K 20 Mar 2025 2024 FY
2023 $5,055,000 -$4,822,000 -49% 01 Jan 2023 31 Dec 2023 10-K 20 Mar 2025 2024 FY
2022 $9,877,000 -$6,610,000 -40% 01 Jan 2022 31 Dec 2022 10-K 20 Mar 2024 2023 FY
2021 $16,487,000 +$12,862,000 +355% 01 Jan 2021 31 Dec 2021 10-K 24 Mar 2023 2022 FY
2020 $3,625,000 01 Jan 2020 31 Dec 2020 10-K 25 Mar 2022 2021 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.